Top 5 Oncology Stocks to Watch According to Barclays

Barclays has identified several promising investment opportunities within the Oncology and Inflammation & Immunology sectors, initiating Overweight ratings on key biopharmaceutical firms including Kymera (KYMR), Janux (JANX), C4 Therapeutics (CCCC), and CytomX (CTMX). The firm highlights these companies for their innovative protein degradation platforms and targeted therapeutics, citing compelling early clinical data for assets like KYMR's KT-621 and JANX's JANX007, significant upcoming catalysts, and perceived undervaluation despite some mixed financial results or clinical setbacks. This analysis underscores a strategic focus on novel therapeutic approaches with substantial upside potential in high-value disease areas.

Analysis

Barclays has initiated bullish coverage on several biopharmaceutical firms within the Oncology and Inflammation & Immunology (I&I) sectors, emphasizing the potential of innovative protein degradation platforms and targeted therapeutics. For Kymera Therapeutics (KYMR), an Overweight rating and $60 price target are anchored to the potential of its STAT6 degrader, KT-621, with key proof-of-concept data expected in Q4 2025, despite the company's recent Q2 2025 revenue of $11.5 million and EPS loss of $0.95 falling short of forecasts. Janux Therapeutics (JANX) is also rated Overweight with a $47 target, with Barclays citing it as 'significantly undervalued' given promising clinical data for its mCRPC drug, JANX007, which has shown competitive efficacy, though the recent departure of its Chief Strategy Officer introduces a governance variable. Conversely, Arvinas (ARVN) is viewed as a value play, trading at a discount to its cash balance following disappointing Phase 3 data for vepdegestrant, which it now plans to out-license with partner Pfizer; Barclays sees upside from its early-stage pipeline. C4 Therapeutics (CCCC) received an Overweight rating based on its lead asset cemsidomide, which achieved a 50% overall response rate in a Phase 1 myeloma trial, positioning it as a potential best-in-class degrader with key data updates expected in late 2025. Finally, CytomX Therapeutics (CTMX) presents a higher-risk profile, with a positive risk-reward assessment on its lead program CX-2051 balanced against a reported Grade 5 treatment-related adverse event and a recent revenue decline, though its cash runway extends to Q2 2027.

Key Decisions for Investors

• Investors should closely monitor upcoming clinical data catalysts for Kymera (KT-621 in Q4 2025) and C4 Therapeutics (cemsidomide in late 2025), as these are the primary inflection points for their respective investment theses.
• Given that Janux is framed as significantly undervalued with strong comparative data, it warrants a valuation check against mCRPC peers, while also considering potential execution risk signaled by the recent C-suite departure.
• For portfolios with higher risk tolerance, Arvinas could be considered a value-based, catalyst-driven turnaround play based on its early-stage pipeline and cash position, while CytomX represents a high-risk, high-reward proposition contingent on resolving the significant safety concerns for its lead asset.
• The mixed financial results and specific clinical or safety setbacks across these names underscore the need for asset-specific due diligence, as a broad thematic investment in protein degradation carries highly differentiated risk profiles from company to company.